Osteoporosis in men and women

Clinical Cornerstone

Volumn 8, Issue 1, 2006, Pages 28-39

  Bonnick, Sydney L ^a,b  

^a UNIVERSITY OF NORTH TEXAS   (United States)

^b Clinical Research Center of North Texas   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

AGING; ARTICLE; BONE DENSITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FRACTURE; HIGH RISK PATIENT; HUMAN; MALE; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OSTEOPOROSIS; RISK FACTORS; SEX FACTORS; TERIPARATIDE;

EID: 34250652856     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(06)80063-3     Document Type: Article

References (47)

1. Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94 (1993) 646-650
2. Available at:. National Osteoporosis Foundation. Accessed September 11. Fast facts (2006). http://www.nof.org/osteoporosis/diseasefacts.htm
3. Campion J.M., and Maricic M.J. Osteoporosis in men. Am Fam Phys 67 (2003) 1521-1526
4. Scane A.C., Sutcliffe A.M., and Francis R.M. Osteoporosis in men. Baillieres Clin Rheumatol 7 (1993) 589-601
5. Kamel H.K. Male osteoporosis: New trends in diagnosis and therapy. Drugs Aging 22 (2005) 741-748
6. van der Klift M., Pols H.A., Geleijnse J.M., et al. Bone mineral density and mortality in elderly men and women: The Rotterdam Study. Bone 30 (2002) 643-648
7. Sigurdsson G., Aspelund T., Chang M., et al. Increasing sex difference in bone strength in old age: The Age, Gene/Environment Susceptibility-Reykjavik study (AGESREYKJAVIK). Bone 39 (2006) 644-651
8. van der Klift M., de Laet C.D., and Pols H.A. Assessment of fracture risk: Who should be treated for osteoporosis?. Best Pract Res Clin Rheumatol 19 (2005) 937-950
9. van der Klift M., de Laet C.E., McCloskey E.V., et al. The incidence of vertebral fractures in men and women: The Rotterdam Study. J Bone Miner Res 17 (2002) 1051-1056
10. Marshall D., Johnell O., and Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312 (1996) 1254-1259
11. van der Klift M., de Laet C.E., McCloskey E.V., et al. Risk factors for incident vertebral fractures in men and women: The Rotterdam Study. J Bone Miner Res 19 (2004) 1172-1180
12. Klotzbuecher C.M., Ross P.D., Landsman P.B., et al. Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis. J Bone Miner Res 15 (2000) 721-739
13. Lim S., Joung H., Shin C.S., et al. Body composition changes with age have gender-specific impacts on bone mineral density. Bone 35 (2004) 792-798
14. Goderie-Plomp H.W., van der Klift M., de Ronde W., et al. Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: The Rotterdam Study. J Clin Endocrinol Metab 89 (2004) 3261-3269
15. Available at:. World Health Organization. Prevention and management of osteoporosis. Accessed September 11. WHO Technical Report series 921 (2006). http://whglibdoc.who.int/trsiWHO_TRS_921.pdf
16. US Preventive Services Task Force. Screening for Osteoporosis in Postmenopausal Women: Recommendations and Rationale (September 2002), Agency for Healthcare Research and Quality, Rockville, Md
17. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis (2003), National Osteoporosis Foundation, Washington, DC
18. AACE. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 Edition, with selected updates for 2003. Endocr Prac 9 (2003) 545-564
19. Management of osteoporosis in postmenopausal women. 2006 Position statement of the North American Menopause Society. Menopause 13 (2006) 340-367
20. ACOG releases recommendations for bone density screening for osteoporosis (2007). http://www.womenschnicseattle.com/bonescan.htm
21. The Writing Group for the ISCD Position Development Conference. Diagnosis of osteoporosis in men, premenopausal women and children. J Clin Densitom 7 (2004) 17-26
22. Binkley N., Bilezikian J.P., Kendler D.L., et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2005 Position Development Conference. J Clin Densitom 9 (2006) 4-14
23. Canadian Panel of the ISCD. Canadian physician pocket guide to BMD testing. International Society for Clinical Densitometry (2004)
24. Black D.M., Cummings S.R., Karpf D.B., et al., Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348 (1996) 1535-1541
25. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280 (1998) 2077-2082
26. Black D.M., Thompson D.E., Bauer D.C., et al., FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 85 (2000) 4118-4124
27. Orwoll E., Ettinger M., Weiss S., et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 343 (2000) 604-610
28. Ringe J.D., Faber H., and Dorst A. Alendronate treatment of established primary osteoporosis in men: Results of a 2-year prospective study. J Clin Endocrinol Metab 86 (2001) 5252-5255
29. Ringe J.D., Dorst A., Faber H., and Ibach K. Alendronate treatment of established primary osteoporosis in men: 3-Year results of a prospective, comparative, two-arm study. Rheumatol Int 24 (2004) 110-113
30. Iwamoto J., Takeda T., Sato Y., and Uzawa M. Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis. Clin Rheumatol 26 (2007) 161-167
31. Sorensen O.H., Crawford G.M., Mulder H., et al. Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience. Bone 32 (2003) 120-126
32. Reginster J., Minne H.W., Sorensen O.H., et al., Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11 (2000) 83-91
33. Harris S.T., Watts N.B., Genant H.K., et al., Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA 282 (1999) 1344-1352
34. McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women: HIP Intervention Program Study Group. N Engl J Med 344 (2001) 333-340
35. Ringe J.D., Faber H., Farahmand P., and Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: Results of a 1-year study. Rheumatol Int 26 (2006) 427-431
36. Sato Y., Iwamoto J., Kanoko T., and Satoh K. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 165 (2005) 1743-1748
37. Sato Y., Iwamoto J., Kanoko T., and Satoh K. Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 64 (2005) 811-816
38. Green J.R. Bisphosphonates: Preclinical review. Oncologist Suppl 9 (2004) 3-13
39. Bonnick S., Saag K.G., Kiel D.P., et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate vs. risedronate over two years. J Clin Endocrinol Metab 91 (2006) 2631-2637
40. Dunford J.E., Thompson K., Coxon F.P., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296 (2001) 235-242
41. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 (2001) 1434-1441
42. Orwoll E.S., Scheele W.H., Paul S., et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18 (2003) 9-17
43. Black D.M., Greenspan S.L., Ensrud K.E., et al., PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349 (2003) 1207-1215
44. Finkelstein J.S., Hayes A., Hunzelman J.L., et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349 (2003) 1216-1226
45. Black D.M., Bilezikian J.P., Ensrud K.E., et al., PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353 (2005) 555-565
46. Lindsay R., Scheele W.H., Neer R., et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164 (2004) 2024-2030
47. Kurland E.S., Heller S.L., Diamond B., et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1-34)]. Osteoporos Int 15 (2004) 992-997